MDMA in two dose strengths shows effectiveness in reducing PTSD symptoms
The Brown University Psychopharmacology Update September 1, 2018 DOI: 10.1002/pu.30352
Summary
AI-generated from the abstractA randomized trial found that military veterans and public safety officers with chronic PTSD experienced a reduction in symptoms when the psychedelic drug MDMA was given in conjunction with psychotherapy. Doses of 75 mg and 125 mg, each administered in two experimental sessions spaced 3 to 5 weeks apart, were more effective than a control dose of 30 mg.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Population | Military veterans and public safety officers with chronic post-traumatic stress disorder |
| Dose | 75 mg, 125 mg, 30 mg |
| Duration | Two experimental sessions spaced 3 to 5 weeks apart |
| Key finding | Doses of 75 mg and 125 mg of MDMA given with psychotherapy were more effective than a 30 mg control dose in reducing PTSD symptoms. |
Abstract
Military veterans and public safety officers with chronic post‐traumatic stress disorder (PTSD) experienced a reduction in symptoms when the psychedelic drug 3,4‐methylenedioxymethamphetamine (MDMA) was given in conjunction with psychotherapy, a randomized trial has found. Doses of 75 mg and 125 mg, each given in two experimental sessions spaced 3 to 5 weeks apart, were more effective than a control dose of 30 mg, researchers reported.